ArticleFrontiers in immunology2026
Delayed B-cell reconstitution in the bone marrow precedes the development of chronic graft-versus-host disease following pediatric hematopoietic stem cell transplantation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Allogeneic hematopoietic stem cell transplantation (HSCT) in children remains challenged by chronic graft-versus-host-disease (cGvHD), significantly affecting morbidity and survival. While aberrant peripheral B-cell reconstitution has been implicated in cGvHD, B-cell development in the bone marrow (BM) remains less explored. Method: We investigated the B-cell reconstitution in BM samples and its potential to predict cGvHD in 76 children undergoing HSCT for acute leukemia (2010-2021) by blinded immunophenotypic analysis. Results: Children developing cGvHD exhibited delayed B-cell reconstitution in the BM with significantly lower proportions of total B cells and early B-cell precursors (BCP) I and II from +2 months to +9 months post-HSCT (all p<0.008) and reduced BCPIII and mature B cells at later time points compared to those without cGvHD (all p<0.05). In multivariable Cox proportional hazards models, low proportions of total B cells, BCPI, and BCPII at month +2 and month +3 were independent risk factors for cGvHD (HR=6.9-14.1, all p<0.017). At +2 months after HSCT, ROC analysis for predicting cGvHD with cut-off values of 0.16% (BCPI) and 0.99% (BCPII), yielded a sensitivity of 1.0 and a specificity of 0.69, while a cut-off value of 2.25% for total B cells resulted in a sensitivity of 0.90 and a specificity of 0.69. Discussion: These findings support previous evidence of disturbed B-cell reconstitution in cGvHD and suggest that phenotypic monitoring of BM B cells following pediatric HSCT may facilitate early cGvHD risk stratification. As BM assessments are routinely performed after HSCT, such monitoring could be readily integrated into existing clinical workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.